The Latest Breaking News from AstraZeneca

Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business

Scientists have offered a new explanation for why COVID-19 vaccines that contained adenoviruses carried a rare-but-serious risk of blood clotting.

Absci, a drug and target discovery company, has been harnessing the power of deep learning AI to develop new and existing disease treatments.

The team discovered that people who previously received AstraZeneca or Sinopharm COVID-19 vaccines had a "non-inferior" immune response when given a half dose of a Pfizer COVID-19 booster vaccine, comparable to those who received a full dose.

Several pharmaceutical companies are racing to develop obesity drugs and tap into a surge in consumer demand for the extremely profitable drugs. Sales of Eli Lilly’s (LLY ) diabetes drug Mounjaro, just approved by the U.S. Food and Drug Administration (FDA) for obesity in the U.S., hit $1.41 billion in...

Only 20% of the top 1,000 companies have targets to reduce their emissions, a sign not enough leaders are taking climate change seriously.

A multi-million-pound landmark “vaccine damage” case is set to take place in London’s High Court. The test case is being pursued by Jamie Scott who suffered a severe brain injury in April 2021 after receiving the Oxford-AstraZeneca vaccine.

AZN stock popped after AstraZeneca said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene.

UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill

Shares in FTSE 100 heavyweight Diageo have tumbled after it cut guidance due to lower-than-expected demand in Latin America and the Caribbean.